These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis. Miller SJ; Li H; Rizvi TA; Huang Y; Johansson G; Bowersock J; Sidani A; Vitullo J; Vogel K; Parysek LM; DeClue JE; Ratner N Mol Cell Biol; 2003 Mar; 23(6):2213-24. PubMed ID: 12612091 [TBL] [Abstract][Full Text] [Related]
9. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448 [TBL] [Abstract][Full Text] [Related]
10. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628 [TBL] [Abstract][Full Text] [Related]
11. Expression of insulin-like growth-factor-1 receptor (IGF-1R) in peripheral nerve sheath tumors in neurofibromatosis type 1. Friedrich RE; Keiner D; Hagel C Anticancer Res; 2007; 27(4A):2085-90. PubMed ID: 17649826 [TBL] [Abstract][Full Text] [Related]
12. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. Subramanian S; Thayanithy V; West RB; Lee CH; Beck AH; Zhu S; Downs-Kelly E; Montgomery K; Goldblum JR; Hogendoorn PC; Corless CL; Oliveira AM; Dry SM; Nielsen TO; Rubin BP; Fletcher JA; Fletcher CD; van de Rijn M J Pathol; 2010 Jan; 220(1):58-70. PubMed ID: 19890883 [TBL] [Abstract][Full Text] [Related]
14. Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient. Perren A; Wiesli P; Schmid S; Montani M; Schmitt A; Schmid C; Moch H; Komminoth P Am J Surg Pathol; 2006 Aug; 30(8):1047-51. PubMed ID: 16861979 [TBL] [Abstract][Full Text] [Related]
15. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Birindelli S; Perrone F; Oggionni M; Lavarino C; Pasini B; Vergani B; Ranzani GN; Pierotti MA; Pilotti S Lab Invest; 2001 Jun; 81(6):833-44. PubMed ID: 11406645 [TBL] [Abstract][Full Text] [Related]
16. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. Lothe RA; Slettan A; Saeter G; Brøgger A; Børresen AL; Nesland JM J Neuropathol Exp Neurol; 1995 Jan; 54(1):65-73. PubMed ID: 7815081 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1. Friedrich RE; Beer C; Glatzel M; Hagel C Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544 [TBL] [Abstract][Full Text] [Related]
18. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Leroy K; Dumas V; Martin-Garcia N; Falzone MC; Voisin MC; Wechsler J; Revuz J; Créange A; Levy E; Lantieri L; Zeller J; Wolkenstein P Arch Dermatol; 2001 Jul; 137(7):908-13. PubMed ID: 11453810 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. Ki DH; He S; Rodig S; Look AT Oncogene; 2017 Feb; 36(8):1058-1068. PubMed ID: 27477693 [TBL] [Abstract][Full Text] [Related]
20. Mouse models of tumor development in neurofibromatosis type 1. Cichowski K; Shih TS; Schmitt E; Santiago S; Reilly K; McLaughlin ME; Bronson RT; Jacks T Science; 1999 Dec; 286(5447):2172-6. PubMed ID: 10591652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]